查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1574948

CRBSI 治疗市场，按药物类别、按给药途径、按适应症、按国家和地区划分 - 2024-2032 年行业分析、市场规模、市场份额和预测

CRBSI Treatment Market, By Drug Class, By Route of Administration, By Indication, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 303 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告要点

2023 年 CRBSI 治疗市场规模为 15.3032 亿美元，2024 年至 2032 年复合年增长率为 5.20%。

CRBSI 处理市场-市场动态

导管相关感染的流行增加了对有效治疗的需求。

导管相关血流感染 (CRBSI) 盛行率的上升是 CRBSI 治疗市场的重要驱动力。患者和医疗保健提供者对 CRBSI 相关风险的认识不断提高，导致人们更加重视预防策略。随着医疗保健行业优先考虑患者安全并努力减少医院获得性感染，对 CRBSI 治疗的需求持续增长，使其成为医疗保健市场研发的关键领域。

根据美国疾病管制与预防中心 (CDC) 的数据，美国每年发生约 25 万例血流感染病例，其中许多与中心静脉导管有关。这凸显了迫切需要有效的治疗和预防措施。医疗机构越来越多地采用先进的感染控制方案，例如抗菌导管，并加强对医护人员的导管护理培训。

CRBSI 治疗市场 - 主要见解

根据我们的研究分析师分享的分析，预计全球市场在预测期内（2024-2032）每年将以 5.20% 左右的复合年增长率成长

根据药物类别细分，预计万古霉素将在 2023 年显示最大市场份额

根据迹象，细菌感染是 2023 年的主要类型

根据给药途径细分，注射剂是 2023 年的主导类型

按地区划分，北美是 2023 年的主要收入来源

CRBSI 治疗市场-細項分析：

全球 CRBSI 治疗市场根据药物类别、给药途径、适应症和地区进行细分。

市面上依药物类别分为七类：氯唑西林、头孢他啶、头孢唑啉、达托霉素、万古霉素、替考拉宁、棘白菌素等。万古霉素是 CRBSI 治疗市场中最主要的部分。这种抗生素对经常引起这些感染的抗甲氧西林金黄色葡萄球菌 (MRSA) 效果很好。医疗保健提供者喜欢它，因为它对多种类型的细菌可靠且有效。万古霉素使用历史悠久，安全记录良好，更值得信赖。随着抗生素抗药性的增加，对万古霉素等有效治疗方法的需求仍然很高。总体而言，其有效性和医疗专业人士的信任使其在 CRBSI 治疗中名列前茅。

根据适应症，市场分为三类：细菌感染、真菌感染、病毒和寄生虫感染以及其他。细菌感染是 CRBSI（导管相关血流感染）治疗市场的最大部分。细菌是这些感染最常见的原因，可能导致严重的健康问题。治疗通常涉及抗生素，它对多种细菌有效。留置导管患者的大量细菌感染增加了对这些治疗的需求。此外，医疗保健提供者专注于减少细菌感染併发症的快速解决方案，这有助于这部分市场的进一步成长。

CRBSI 处理市场 - 地理洞察

北美导管相关血流感染（CRBSI）治疗市场正在快速成长。这一增长主要是因为越来越多的人入院并使用中心静脉导管。医院正致力于更好地控制感染，增加对有效治疗的需求。政府对感染控制计画的支持也是该市场的重要驱动力。更严格的医疗保健法规鼓励医院采用改进的做法和产品。因此，患者正在接受更安全、更有效的照护。

CRBSI 处理市场-竞争格局：

导管相关血流感染 (CRBSI) 市场竞争激烈，包括 Bard Medical (BD)、Medtronic 和 Teleflex 等重要公司。巴德医疗以其创新的导管设计而闻名。美敦力（Medtronic）在世界各地提供广泛的产品。泰利福透过先进的设计来预防感染，并注重病人安全。

Smith's Medical 专注于血管通路，并高度重视品质和安全性。 Fresenius Kabi 以其重症监护产品而闻名，AngioDynamics 则专注于微创手术。 B. Braun Melsungen AG 提供各种医疗设备并重视永续性。这些公司努力创造新的解决方案并改善感染预防，使市场活跃且充满活力。

最新进展：

2023 年 8 月，Citius Pharmaceuticals, Inc. 宣布了 Mino-Lok 临床试验的一个重要里程碑，Mino-Lok 是一种抗生素封管溶液，旨在保存导管相关血流感染患者的导管。该公司报告称，完成试验所需的 92 项任务都已完成。一些患者仍在接受治疗，这可能会导致其他事件。

2023 年 7 月，Teva Pharmaceuticals, Inc. 和 Alvotech 透露，他们打算加强现有的策略合作伙伴关係，旨在开发和推出多种生物相似药候选药物。作为此次合作的一部分，Teva 将透过购买 Alvotech 发行的次级可转换债券来额外投资 4,000 万美元。

目录

第一章：CRBSI 治疗市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 按药物类别分類的 CRBSI 治疗市场片段
    • CRBSI 治疗市场片段（依给药途径）
    • CRBSI 治疗市场片段（按适应症）
    • CRBSI 治疗市场片段（按国家/地区）
    • 按地区分類的 CRBSI 治疗市场片段
  • 竞争洞察

第 3 章：CRBSI 主要市场趋势

  • CRBSI 治疗市场驱动因素
    • 市场驱动因素的影响分析
  • CRBSI 治疗市场限制
    • 市场限制影响分析
  • CRBSI 处理市场机会
  • CRBSI 治疗市场未来趋势

第 4 章：CRBSI 产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：CRBSI 治疗市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：CRBSI 处理市场格局

  • CRBSI 治疗市场占有率分析，2023 年
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：CRBSI 治疗市场 - 按药物类别

  • 概述
    • 按药物类别分類的细分市场份额分析
    • 邻氯西林
    • 头孢他啶
    • 头孢唑啉
    • 达托霉素
    • 万古霉素
    • 替考拉宁
    • 棘白菌素
    • 其他的

第 8 章：CRBSI 治疗市场 - 按给药途径

  • 概述
    • 按给药途径分類的细分市场份额分析
    • 口服
    • 可注射

第 9 章：CRBSI 治疗市场 - 按适应症分类

  • 概述
    • 按指标分類的细分市场占有率分析
    • 细菌感染
    • 霉菌感染
    • 病毒和寄生虫感染
    • 其他的

第 10 章：CRBSI 治疗市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • CRBSI 北美主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按药物类别）
    • 北美市场规模与预测（按管理途径）
    • 北美市场规模和预测（按指标）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • CRBSI 欧洲主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模和预测（按药物类别）
    • 欧洲市场规模与预测（按管理途径）
    • 欧洲市场规模与预测（按指标）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • CRBSI 亚太地区主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模和预测（按药物类别）
    • 亚太地区市场规模与预测（依管理途径）
    • 亚太地区市场规模与预测（依指标）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • CRBSI 拉丁美洲主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按药物类别）
    • 拉丁美洲市场规模与预测（按管理途径）
    • 拉丁美洲市场规模与预测（按指标）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • CRBSI 中东和非洲主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按药物类别）
    • 中东和非洲市场规模及预测（按管理途径）
    • 中东和非洲市场规模及预测（依指标）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 11 章：主要供应商分析 - CRBSI 产业

  • 竞争仪表板
  • 公司简介
    • Bard Medical
    • Medtronic
    • Teleflex
    • Smith's Medical
    • Halyard Health
    • Fresenius Kabi
    • AngioDynamics
    • Vygon
    • B. Braun Melsungen AG
    • Nipro Corporation
    • Cook Medical
    • Amsino International
    • Merit Medical Systems
    • Pall Corporation
    • CR Bard
    • Ruhof Healthcare
    • Inspire Medical Systems
    • Abbott Laboratories

第 12 章：360 度分析师视角

第 13 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV3951

REPORT HIGHLIGHT

CRBSI Treatment Market size was valued at USD 1,530.32 Million in 2023, expanding at a CAGR of 5.20% from 2024 to 2032.

CRBSI stands for Catheter-Related Bloodstream Infections. It happens when bacteria enter the bloodstream through a catheter, a tube used for medical treatments. The treatment market for CRBSI includes various products and therapies designed to prevent and manage these infections. This market offers antibiotics, antiseptics, and advanced catheter designs that reduce infection risk. Hospitals and healthcare providers invest in these solutions to improve patient safety and outcomes. The goal is to minimize infections, which can lead to serious health issues and longer hospital stays.

CRBSI Treatment Market- Market Dynamics

The prevalence of catheter-related infections boosts demand for effective treatments.

The rising prevalence of catheter-related bloodstream infections (CRBSI) is a significant driver for the CRBSI treatment market. Growing awareness among patients and healthcare providers about the risks associated with CRBSIs is leading to a greater emphasis on prevention strategies. As the healthcare sector prioritizes patient safety and strives to reduce hospital-acquired infections, the demand for CRBSI treatments continues to grow, making it a crucial area for research and development in the healthcare market.

According to the Centers for Disease Control and Prevention (CDC), about 250,000 cases of bloodstream infections occur in the U.S. each year, with many linked to central line catheters. This highlights the urgent need for effective treatments and preventive measures. Healthcare institutions are increasingly adopting advanced infection control protocols, such as antimicrobial-impregnated catheters, and enhanced training for healthcare staff on catheter care.

CRBSI Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.20% over the forecast period (2024-2032)

Based on Drug Class segmentation, Vancomycin was predicted to show maximum market share in the year 2023

Based on indication, Bacterial Infections was the leading type in 2023

Based on Route of Administration segmentation, Injectable was the leading type in 2023

based on Region, North America was the leading revenue generator in 2023

CRBSI Treatment Market- Segmentation Analysis:

The Global CRBSI Treatment Market is segmented based on Drug Class, Route of Administration, Indication, and Region.

The market is divided into Seven categories based on Drug Class: Cloxacillin, Ceftazidime, Cefazoline, Daptomycin, Vancomycin, Teicoplanin, Echinocandin, and Others. Vancomycin is the most dominant segment in the CRBSI treatment market. This antibiotic works well against methicillin-resistant Staphylococcus aureus (MRSA), which often causes these infections. Healthcare providers like it because it is reliable and effective against many types of bacteria. Vancomycin has been used for a long time and has a strong safety record, making it even more trusted. As antibiotic resistance increases, the need for effective treatments like Vancomycin is still high. Overall, its effectiveness and the trust of medical professionals keep it at the top of CRBSI treatment.

The market is divided into three categories based on the Indication: Bacterial Infections, Fungal Infections, Viral and Parasitic Infections, and Others. Bacterial infections are the biggest part of the CRBSI (Catheter-Related Bloodstream Infection) treatment market. bacteria are the most common cause of these infections and can lead to serious health problems. Treatments usually involve antibiotics, which are effective against many types of bacteria. The high number of bacterial infections in patients with catheters increases the demand for these treatments. Also, healthcare providers focus on quick solutions to reduce complications from bacterial infections, which helps this part of the market grow even more.

CRBSI Treatment Market- Geographical Insights

North America's catheter-related bloodstream infection (CRBSI) treatment market is growing quickly. This growth is mainly because more people are admitted to hospitals and using central venous catheters. Hospitals are focusing on better infection control, increasing the demand for effective treatments. Government support for infection control programs is also an important driver for this market. Stricter healthcare regulations encourage hospitals to adopt improved practices and products. As a result, patients are receiving safer and more effective care.

CRBSI Treatment Market- Competitive Landscape:

The catheter-related bloodstream infections (CRBSI) market is competitive and includes important companies like Bard Medical (BD), Medtronic, and Teleflex. Bard Medical is known for its innovative catheter designs. Medtronic offers a wide range of products around the world. Teleflex focuses on patient safety with advanced designs to prevent infections.

Smith's Medical specializes in vascular access and puts a strong emphasis on quality and safety. Fresenius Kabi is well-known for its critical care products, and AngioDynamics focuses on minimally invasive procedures. B. Braun Melsungen AG offers a variety of medical devices and values sustainability. These companies work hard to create new solutions and improve infection prevention, making the market active and dynamic.

Recent Developments:

In August 2023, Citius Pharmaceuticals, Inc. announced a significant milestone for the clinical trial of Mino-Lok, an antibiotic lock solution designed to preserve catheters in patients with catheter-related bloodstream infections. The company reported that all 92 required events to complete the trial have been achieved. Some patients are still undergoing treatment, which may result in additional events.

In July 2023, Teva Pharmaceuticals, Inc. and Alvotech revealed their intention to strengthen their existing strategic partnership aimed at developing and launching several biosimilar candidates. As part of this collaboration, Teva will invest an additional US$ 40 million by purchasing subordinated convertible bonds to be issued by Alvotech.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CRBSI TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Bard Medical
  • Medtronic
  • Teleflex
  • Smith's Medical
  • Halyard Health
  • Fresenius Kabi
  • AngioDynamics
  • Vygon
  • B. Braun Melsungen AG
  • Nipro Corporation
  • Cook Medical
  • Amsino International
  • Merit Medical Systems
  • Pall Corporation
  • C.R. Bard
  • Ruhof Healthcare
  • Inspire Medical Systems
  • Abbott Laboratories

GLOBAL CRBSI TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Cloxacillin
  • Ceftazidime
  • Cefazoline
  • Daptomycin
  • Vancomycin
  • Teicoplanin
  • Echinocandin
  • Others

GLOBAL CRBSI TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Injectable

GLOBAL CRBSI TREATMENT MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Bacterial Infections
  • Fungal Infection
  • Viral and Parasitic Infections
  • Others

GLOBAL CRBSI TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. CRBSI Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. CRBSI Treatment Market Snippet by Drug Class
    • 2.1.2. CRBSI Treatment Market Snippet by Route of Administration
    • 2.1.3. CRBSI Treatment Market Snippet by Indication
    • 2.1.4. CRBSI Treatment Market Snippet by Country
    • 2.1.5. CRBSI Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. CRBSI Key Market Trends

  • 3.1. CRBSI Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. CRBSI Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. CRBSI Treatment Market Opportunities
  • 3.4. CRBSI Treatment Market Future Trends

4. CRBSI Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. CRBSI Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. CRBSI Treatment Market Landscape

  • 6.1. CRBSI Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. CRBSI Treatment Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 7.1.2. Cloxacillin
    • 7.1.3. Ceftazidime
    • 7.1.4. Cefazoline
    • 7.1.5. Daptomycin
    • 7.1.6. Vancomycin
    • 7.1.7. Teicoplanin
    • 7.1.8. Echinocandin
    • 7.1.9. Others

8. CRBSI Treatment Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 8.1.2. Oral
    • 8.1.3. Injectable

9. CRBSI Treatment Market - By Indication

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
    • 9.1.2. Bacterial Infections
    • 9.1.3. Fungal Infection
    • 9.1.4. Viral and Parasitic Infections
    • 9.1.5. Others

10. CRBSI Treatment Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. CRBSI Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. CRBSI Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. CRBSI Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. CRBSI Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. CRBSI Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- CRBSI Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Bard Medical
    • 11.2.2. Medtronic
    • 11.2.3. Teleflex
    • 11.2.4. Smith's Medical
    • 11.2.5. Halyard Health
    • 11.2.6. Fresenius Kabi
    • 11.2.7. AngioDynamics
    • 11.2.8. Vygon
    • 11.2.9. B. Braun Melsungen AG
    • 11.2.10. Nipro Corporation
    • 11.2.11. Cook Medical
    • 11.2.12. Amsino International
    • 11.2.13. Merit Medical Systems
    • 11.2.14. Pall Corporation
    • 11.2.15. C.R. Bard
    • 11.2.16. Ruhof Healthcare
    • 11.2.17. Inspire Medical Systems
    • 11.2.18. Abbott Laboratories

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us